The present study, with the inclusion of all available RCTs regarding lapatinib combined to neoadjuvant therapy, provides evidence that the addition of lapatinib to neoadjuvant chemotherapy in HER2-positive breast cancer patients results in a significant increase in the pCR rate. Here, ERBB2 is linked to breast cancer.